CH696659A9 - Cosmetic composition for the treatment and / or prevention of skin smagllature - Google Patents

Description

CH 696 659 A9

Description

[0001] The present invention refers to a cosmetic composition for the treatment and / or prevention of skin stretch marks.

[0002] The present invention originates in the cosmetic sector and in particular in the field of anti-smear preparations.

[0003] Stretch marks, also known as "strie distensae" or "strie atrophicae" are a type of skin atrophy characterized by linear, well-defined depressions, generally of an asymptomatic nature, particularly widespread in female individuals.

[0004] The striae may appear in any part of the body, with the exception of the face and extremities. Generally they arise bilaterally. They are formed mainly in areas subject to rapid tension in a short period of time, following lacerations of the connective tissue of the dermis. The most frequently affected site is the abdominal region where the disposition is variable since the direction of maximum skin tension is not constant and can undergo changes for various reasons (pre- and post-pregnancy); on the sides they are often transversal; on the thighs they are mostly oblique to the inner surface; in the lumbosacral area they are horizontal. They also appear frequently on the breast.

[0005] They appear as linear bands, separated by stretches of healthy skin, with sharp edges. They are several centimeters long and 3 to 10 mm wide. From a histological point of view the stria corresponds to a thinning of the epidermis with atrophy of the dermal collagen bundles, associated with reduction of the elastic fibers which, at the edges of the stretch mark, appear retracted and thinned. This area of atrophy is not vascularized.

[0006] Their onset is generally asymptomatic, although it can sometimes be accompanied by a slight itchy sensation. The color depends on their evolutionary phase: at the beginning when the inflammatory component prevails, the color varies from pink, to violet pink, or to bluish red, while subsequently, in the cicatricial phase, the striae are thinner, pleated and become whitish.

[0007] Stretch marks affect the female sex twice as often as men; may appear at any age but prefer puberty.

[0008] In pregnancy about 55-90% of women are affected.

[0009] The main physiological states that can determine the appearance of stretch marks are the following: puberty, pregnancy, more or less intensive sports practice due to increased muscles, rapid weight loss and / or weight gain. Also the mechanical distension induced by a rapid and sudden, or small and repeated trauma can induce the formation of striae.

[0010] The pathophysiological mechanism of striae formation is still little known. However, it seems that the triggering causes are mainly due to i) a biochemical-hormonal factor and ii) a mechanical stretching factor, that is an exaggerated tension of the skin due to a sudden variation both in excess and in defect of the adipose panniculus or of certain parts of the body such as the abdomen, buttocks and thighs.

[0011] The hormonal factor determines loss of elasticity and decrease of the connective fibers; the hormones (essentially corticosteroids) in fact interfere with the activity of fibroblasts, on the quality and quantity of collagen and elastic fibers, on the characteristics of the fundamental substance and on the functionality of the microcirculation. The mechanical distension factor that would cause the breakage of collagen fibers acts on this soil.

[0012] Repeated local microtraumas or progressive stretching of the skin would also cause a stretching of the dermal capillaries, with a consequent decreased blood flow to the skin structures and consequent district ischemia; the reduction in the intake of oxygen and nutrients would create metabolic suffering, aggravating atrophy.

[0013] The formation of stretch marks, essentially, occurs at three different times:

- a pre-clinical (or inflammatory) phase characterized by a block of fibroblast function and a chemical-physical modification of the fundamental substance (decrease in mucopolysaccharides and decreased activity of glycolic enzymes), with consequent alteration of collagen and elastic fibers ;

- a regenerative phase, corresponding clinically to Striae rubrae, characterized by the resumption of enzymatic activity, with reactivation of fibroblasts, increase in mast cells, restoration of the production of mucopolysaccharides;

- a healing phase, corresponding clinically to the Striae albae, in which we witness the normalization of the enzymatic activity of the fibroblasts, the regeneration first of the collagen fibers and then of the elastic fibers with restoration of the damaged connective tissue.

[0014] The histological aspect of the Striae differs according to their evolutionary phase. In preclinical phases and in very initial lesions the epidermis does not appear modified. The biochemical alterations of the fundamental substance and of the fibrous component, which will create the conditions for the formation of the stretch mark, are manifested by type I and III procollagen and by fibronectin. In the rubrae striae the collagen fibers are still not very compact and separated from the dermis, they are arranged parallel to the skin surface and their structure appears almost normal. The elastic fibers are more elongated. There is also a modest perivascular lymphocytic infiltrate with mononuclear cells and an increase in Langherans cells in the dermis. Mast cells appear degranulated and the release of trypsin and chymotrypsin causes collagenolysis and elastolysis particularly in the center of the stretch mark in formation. Subsequently the epidermis becomes

2

CH 696 659 A9

thin and flattened and with loss of papillary pattern. Also the dermis is thinned, besides being considerably altered in the collagen and in the elastic component. In the intermediate and deep dermis there is a pronounced elastolysis related to the fact that the macrophages release elastase. In the upper part of the dermis, collagen is made up of thin and elongated bundles parallel to the skin surface, while below the bundles are compacted, thicker and irregularly arranged. Fibroblasts are quiescent. This compaction would be linked to a reduction of the fundamental amorphous substance of the connective tissue, due to the low production of acidic mucopolysaccharides. Elastic tissue may appear differently depending on whether the biopsy was performed at an early or late stage. In general, in the superficial part of the dermis the elastic fibers are elongated and arranged parallel to the epidermis. In the underlying dermis they are more rarefied and fragmented, smaller than normal but more numerous than in intact skin.

[0015] Stretch marks today are no longer to be considered as indelible lesions, although often the possibility of a regression remains limited and in any case conditioned by the period of onset of the striae and by the stage of their healing process.

[0016] Numerous cosmetic preparations with anti-stretch marks are currently available on the market.

[0017] Some of these preparations with an anti-stretch mark action, however, contain active ingredients of synthetic origin whose prolonged use can determine the onset of local and non-local side effects.

[0018] Other known anti-skinning preparations have a cosmetic effectiveness which is not always completely satisfactory.

[0019] At the present time it is therefore possible to have available new formulations for cosmetic use provided with a satisfactory ability to treat and prevent the formation of stretch marks.

[0020] One of the purposes of the present invention therefore consists in providing a cosmetic composition for the local application capable of treating both the already existing stretch marks, attenuating their visibility and preventing their formation.

[0021] In particular, the Applicant has identified that by combining a base formulation containing the active ingredients matrichina / e, rutin, phaseolus lunatus extract with at least one other selected active ingredient provided with activity on one of the components at the origin of the stretch marks, a synergistic effect is obtained by attenuating the visibility of stretch marks and limiting their onset.

[0022] According to a first aspect of the present invention there is therefore provided a cosmetic composition for the treatment / prevention of stretch marks comprising the association of matrichina / e, rutin, phaseolus extract preferably of the genus lunatus with one or more selected active principles among aloe vera extract, vitamin E, sericin, blood delery extract, Saccharomices lysate, chlorella algae extract, lipopeptide comprising Lis-Thr-Thr-Lis-Ser.

[0023] According to this aspect, the composition of the invention provides a set of basic active principles (base formulation), each of which has its own specific activity, which works in synergy with one or more additional active ingredients which by acting on different or complementary ways of forming stretch marks, they allow intervention under different profiles with a complete and synergistic method.

[0024] Typically, the composition of the invention, by stimulating the cellular reproduction of the connective tissue and the related production of collagen fibers suitable for restoring the damaged tissue, is able to attenuate the redness that accompanies the appearance of stretch marks, to elasticize and hydrate , soothe and smooth the treated skin area.

[0025] It has also been observed that the composition of the invention possesses in addition to the cosmetic properties previously exposed also an ability to improve skin microcirculation.

[0026] Typically the composition of the invention can be presented in any formulation suitable for cutaneous application such as the forms in cream, emulsions, gels, milks, oils, etc.

[0027] The use of the composition of the invention provides for the local application of a cosmetically effective quantity on the area affected by the stretch mark and on the body areas which are most typically affected by their formation.

[0028] Conveniently, in the basic formulation of the composition of the invention there are present A) one or more tricholine, B) rutin and C) an extract of phaseolus in particular of the genus lunatus.

[0029] A) The matrichines are peptide fragments with a sequence less than or equal to 20 amino acids. They are formed by the proteolysis of the extracellular matrix and are able to regulate cellular activity.

[0030] According to an embodiment in the composition of the invention, matrichines containing peptide fragments with 3 or 4 amino acids (tri or tetrapeptide) are used.

[0031] Two matrichines are particularly suitable, the peptides Glycyl-lstidyl-Lysine and Glycyl-Glutaminyl-Prolyl-Arginine (both conveniently with molecular weight 200 ppm), involved in the synthesis of the dermal matrix, in particular of collagen, the main protein of the tissue connective, and of fibronectin, molecule responsible for the connection between the extracellular matrix and the cell surface.

[0032] These two matrichines also promote the cellular proliferation of keratinocytes and fibroblasts, therefore they prove to be effective in the reconstruction of the extracellular dermal matrix.

3

CH 696 659 A9

[0033] The first, the glycine-histidine-lysine tripeptide derives from the collagen I a2 chain. The biological activity of said tripep-tide has been described in numerous in vitro studies, which have shown an increase in collagen synthesis ( + 350%) and glycosaminoglycans (+ 46%), and also a reparative and protective action against collagen.

[0034] The second matrichine, the glycine-glutamine-proline-arginine tetrapeptide, is a natural fragment of the IgG immunoglobulin which is endowed with various biological activities above all immunological. The biological activity of the tetrapeptide has been described in numerous in vitro studies which have allowed to highlight a decrease in the secretion of interleukin 6 (IL6) by keratinocytes, responsible for the inflammatory process. An in vivo test instead showed firming activity (+ 19%), elasticising (+ 17%) and moisturizing (+ 24%) of the tetrapeptide.

[0035] B) Rutin, the second component of the basic formulation, has antioxidant properties, stabilizes mast cells and inhibits leukocyte elastase. The plant extract inhibits proteolytic enzymes, such as trypsin and chymotrypsin, released during the inflammatory phase which leads to the formation of stretch marks.

[0036] C) The third component of the basic formulation is an extract, operated with traditional techniques, of the bean plant in particular of the genus Phaseolus Lunatus.

[0037] An in vitro test was performed in which trypsin, chymotrypsin and elastase were incubated with the base formulation containing the three components previously described at different concentrations.

[0038] The inhibition kinetics were monitored for several minutes. The set of the two matrichines with Rutin and plant extract inhibits proteolytic enzymes according to a dose-dependent trend.

[0039] At the 4% concentration of the association described above, the inhibition of the enzyme activities are the following: trypsin -58%, chymotrypsin -15% and elastase -90%.

[0040] A second in vitro test was performed by incubating human fibroblasts with 2% of the association of three components described above. After incubation the collagen I and the fibronectins produced by the cells are quantified by immunoassay and visualized with immunofluorescence. The association stimulates the neosynthesis of the matrix macromolecules: collagen I + 102% and fibronectin + 91% compared to the control.

[0041] An in vivo test was performed: 13 volunteers with problems with stretch marks due to weight gain applied a cream containing the basic formulation of A) two matrichines twice a day: the tripeptide glycine-histidine-lysine and the tetrapeptide glycine-glutamine-proline-arginine, B) Rutin and C) phaseoulus plant extract: the characterization of stretch marks was performed by ultrasound and a dermatologist's evaluation. The ultrasounds allowed to verify the average increase of the thickness of the skinned skin (+ 10.8%) and the decrease of the stretch mark depression (-72.5%) after the treatment. The dermatologist has evaluated the variations in color, relief and width of the stretch by assigning a score ranging from 0 to 10. After the treatment the average variations observed were: color -21.7%, relief -21.9% and width of stretch marks -26.7%.

[0042] Aloe vera, the active ingredient used in an embodiment of the composition of the invention, has anti-reddening, soothing and moisturizing properties. It also has very interesting healing properties for the treatment of stretch marks; the application on artificial skin has shown that the glycoproteins contained in it are able to stimulate the formation of epidermal tissue, promoting the formation of new cells. In the tissue in contact with the active principle there is an increase in the epidermal growth factor, in fibronectin and keratin and in the cellular receptors to which these substances bind physiologically; there is an accelerated migration of keratinocytes and an increase in the expression of factors related to cell proliferation.

[0043] The anti-inflammatory and antioxidant properties of aloe are mainly due to the presence of superoxide dismutase isoenzymes, as well as immunostimulants, thanks to the presence of acemannan.

[0044] The rich polysaccharide composition of Aloe vera extracts can give moisturizing properties to the cosmetic product. A study made it possible to evaluate, through skin bio-engineering techniques, the effect of cosmetic formulations with different concentrations of freeze-dried extract of Aloe vera. The results obtained indicate that the freeze-dried extract of Aloe vera is a natural ingredient that can improve skin hydration, probably through a humectant type mechanism.

[0045] Vitamin E, the active ingredient used in an embodiment of the composition of the invention, protects the lipids and lipoproteins of cell membranes and therefore has a beneficial effect on the ability to bind water to the skin. Improves the barrier functions of the epidermis by decreasing the Trans Epidemial Water Loss (TEWL). It is therefore considered the natural moisturizer for the skin and ideal substance for dry skin.

[0046] It has an anti-inflammatory action. In particular, the hydrophilic derivative of y-tocopherol significantly inhibits the production of Prostaglandins E2 (PGE2), secondary messengers of the inflammation signal and the production of cyclooxygenase 2 (COX-2), a key enzyme required for the synthesis of PGE2 .

[0047] Sericin, used in an embodiment of the composition of the invention, represents the second silk protein, after fibroin. It is a globular protein whose amino acid composition is as follows: alanine, glycine, isoleucine, leucine, proline, valine, tyrosine, asparagine, glutamine, arginine, histidine, lysine, serine, threonine.

4

CH 696 659 A9

[0048] In aqueous solution, applied to the skin, it initially forms a viscous film which, after drying, gives a sensation of smooth, velvety, cured skin. Film-forming capabilities increase with increasing molecular weight. Due to its conformation and the presence of numerous hydrophilic areas and oligosaccharide chains, Sericin is able to improve the structure of skin hydration. The dynamic measurement of the Trans Epidermal Water Loss, related to the exchange of moisture between skin and the external environment, has given satisfactory results: the Sericin has a marked moisturizing effect, with action, prolonged over time, to increase the epidermal barrier. The moisturizing action is mainly linked to the film-forming effect, without occlusion. Sericin has also shown a marked smoothing effect on skin irregularities. Casts of skin reliefs were performed both before and after 21 days of treatment with Sericin cream: the results showed a clear attenuation of skin irregularities.

[0049] Sericin is known to increase the adhesion and growth of cultured fibroblasts.

[0050] Recently the effect of Sericin on human fibroblast cultures has been examined to test its application on skin lesions. It was verified that when human fibroblasts were cultured with 2.5 or 25 micr / cm2 of Sericin, the cell count after 72 hours of cultivation was 150% more than the negative control. The adhesion and consequent proliferation of fibroblasts can play an important role in wound healing and therefore find a valid application in the field of stretch marks treatment.

[0051] Delineate sanguinea, used as an extract in an embodiment of the composition of the invention, is a red alga of the Rodoficee class.

[0052] It grows in the North Sea and in the north of the Atlantic.

[0053] Typically, the extract of Delesseria sanguinea, used as an active ingredient in an embodiment of the invention, is obtained through a procedure that comprises the steps of

- collection of algae

- selection of algae

- freezing at -20 ° C

- drying

- osmotic shock with addition of water

- percolation of the solvent

- solvent recirculation for about 1.5 hours

- concentration and obtaining of the finished product

[0054] Delesseria extract has positive effects on subcutaneous microcirculation. The effect of the Delesseria extract was evaluated using a 5% carbopol extract gel and applying it on the forearm of 15 volunteers twice a day for 28 days. The test was performed against placebo. Surface microcirculation was measured through measurements of thermal conductivity using a thermal probe applied directly to the skin. It is known that thermal conductivity is directly proportional to skin microcirculation. After 28 days of application twice a day the placebo did not change the microcirculation (+ 0.11 +/- 0.12 mW / cm ° C).

[0055] While the gel containing 5% Delesseria extract has significantly increased skin microcirculation (+ 0.48 +/- 0.21 mW / cm ° C).

[0056] This effect was observed in 80% of volunteers.

[0057] The Saccharomices lysate, used in an embodiment of the composition of the invention, typically contains active substances of low molecular weight which are derived from yeast cultures, produced under aerobic conditions, of the species "Saccharomices cerevisiae". This lysate reactivates cellular tissue regeneration. Typically, the following amino acids are included in its composition: aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, arginine, cystine.

[0058] To obtain the lysate the following production steps can be followed:

1.

preculture

2.

aerobic fermentation

3.

cell collection

4.

selective cell lysis

5.

subcellular fractionation

6.

separation of insoluble fragments

7.

obtaining the raw fraction

8.

selective precipitation

9.

purification

10.

concentration of the active fraction

11.

membrane filtration

12.

obtaining the active, purified fraction

13.

sterilizing filtration

5

CH 696 659 A9

[0059] An evaluation study was performed on the stimulation of cell turnover using the dansile chloride technique. On the forearm of 12 volunteers, in 3 different zones, a 5% vaseline oil solution of dansile chloride in the amount of about 4 mg / cm2 was applied. A non-occlusive bandage was placed over each treated area. After 24 hours the bandages were removed and the treated areas were with a special lamp to monitor the fluorescence intensity. 13 sites of each forearm were treated with the product twice a day. On days 1,7,10 and all subsequent days the subjects were visited and the variation in fluorescence intensity due to dansil chloride was evaluated. The endpoint (elimination of all color) was determined and then calculated the percentage increase in cell renewal rate.

[0060] The "Saccharomices cerevisiae" lysate produced an increase in cell turnover of 17% to 3% of active and 25% to 5% of active.

[0061] The Chlorella seaweed extract, used in an embodiment of the composition of the invention, is obtained from cultures of a unicellular green microalgae, Chlorella alga.

[0062] The alga is grown in polyethylene tubes which allow the conservation of monospecific crops. The main processing steps for obtaining the Chlorella extract include:

1. solubilization of chlorella in water

2. soluble and insoluble phase separation by filtration

3. sterilizing filtration of the soluble part

[0063] Chlorella seaweed extract has a high content of trace elements (iron, copper, zinc, manganese), minerals (sodium, potassium, calcium) and amino acids, 60% of which is represented by essential amino acids (isoleucine, methionine, phenylalanine, threonine, tryptophan, valine, arginine, histidine).

[0064] Among the amino acids arginine, present in high quantities, is a precursor of ornithine, in turn a precursor of spermine and spermidine, these latter non-peptide growth factors that have the ability to stimulate cell division and activate synthesis protein.

[0065] Finally, the high content of water-soluble vitamins (B1, B2, B12, PP) effectively acts on protein synthesis. In fact, acting as mediators, they promote the release of energy in the form of ATP, either directly through the Krebs cycle (vitamin B1) or through the respiratory chain (vitamin B2, PP). This energy is quickly reused to replenish protein synthesis.

[0066] From the in vitro tests performed on the chlorella algae extract it appears that it is able to stimulate cell proliferation. Using cell cultures in suboptimal conditions, which simulate a deficient state of growth factors and nutritive elements, a strong multiplication activity of the treated cells is highlighted, compared to the untreated cells.

[0067] A further component, present in an embodiment of the composition of the invention consists of a synthesis lipopeptide, having the Lis-Thr-Thr-Lis-Ser sequence (typically 100 ppm). In vitro studies show that this lipopeptide causes cells to synthesize collagen and glycosaminoglycans.

[0068] Said lipopeptide carries a molecule of palmitic acid attached to the amino acid sequence described above in order to increase its affinity to the skin and its bioavailability.

[0069] In vitro studies have been carried out on the said lipopeptide, as described below.

In vitro test

[0070] The test adopted wanted to demonstrate the ability of the Peptide to stimulate the neo-synthesis of type IV collagen, which is particularly important for the dermo-epidermal junction of the skin (the latter linked to skin elasticity); after cultivating human fibroblasts with and without the Peptide at different concentrations, the newly synthesized proteins were collected in the culture medium. At the concentrations tested, the Peptide resulted in an increase in the production of type IV collagen equal to 50% compared to the control (fibroblast culture without Peptide).

[0071] The production of soluble collagen IV is increased by a factor of between 2 and 4, based on the concentration of the Peptide.

[0072] Another important category of molecules whose production is stimulated by the Peptide is that represented by glycosaminoglycans.

[0073] Human fibroblasts were incubated for 24 hours with and without the Peptide in the presence of a radiolabelled precursor, 3H-glucosamine, which is incorporated into the newly synthesized glycosaminoglycans. These GAGs are secreted by the fibroblasts and deposited in the culture medium. II Peptide significantly increased GAG synthesis: + 267% compared to the control culture at 2% concentration.

[0074] A particularly preferred embodiment of the invention provides for the association of the base formulation containing matrichines, rutin and phaseolus extract preferably of the genus lunatus with aloe vera extract, vitamin E, sericin, extract of bloodstone, Saccharomices lysate, Chlorella seaweed extract, lysine-threonine-threonine-lysine-serine amino acid sequence lipopeptide (Lis-Thr-Thr-Lis-Ser).

6

CH 696 659 A9

[0075] In accordance with another aspect of the present invention there is provided a method of treating and / or preventing stretch marks comprising applying a cosmetically effective quantity of a composition comprising matrichin / e, rutin, extract of phaseolus lunatus in association with one or more active ingredients selected from aloe vera extract, vitamin E, sericin, bloodline extract, Saccharomices lysate, chlorella algae extract, lipopeptide comprising Lis-Thr-Thr-Lis-Ser.

[0076] It has been observed that the use of a cosmetic composition of this type produces the following effects:

1. reactivation of fibroblast activity to restore the production of collagen, fibronectin and elastin and inhibition of proteolytic enzymes responsible for the degradation of the dermal matrix thanks to the activity of the matrichines together with rutin and the plant extract. The new fibers go to rebuild the damaged connective tissue with reduced inflammation.

2. stimulation of fibroblast proliferation and production of the fundamental amorphous substance of the dermis to restore dermis thickness, thinning out during the development of the stretch mark thanks to the presence of Chlorella seaweed extract and Palmitoyl-Lys-Thr-Thr-Lys Peptide Ser.

3. restoration of local subcutaneous microcirculation and the consequent supply of nutrients and oxygen with consequent improvement of the trophism of the area affected by stretch marks, thanks to the extract of Delesseria sanguinea.

4. soothing and anti-reddening action, especially important during the inflammatory phase of the stretch due to the presence of Aloe. Aloe is also important as it stimulates the formation of epidermal tissue.

5. moisturizing and emollient action of vitamin E; helps to restore the elasticity of the skin, which in this way is more resistant to stretching and mechanical stress.

6. smoothing action on skin irregularities thanks to silk proteins; the skin is soft and fluffy. It also contributes to skin hydration.

7. release of the superficial cutaneous layer constituted by dead cells, thanks to the lysate of «Saccharomices cerevi-siae» which allows to smooth the skin, making it smoother and more compact and, at the same time, improves the penetration capacity of the cosmetic product that is applied .

[0077] For the preparation of the cosmetic compositions of the invention, the apparatuses currently available to the technologies are used according to methods known to those skilled in the art.

[0078] The active ingredients are added and dispersed within a physiologically acceptable vehicle according to methods known to the experts, conveniently adding one or more additive substances such as stabilizers, emulsifiers, excipients, preservatives, perfumes and suspending agents.

[0079] Conveniently, the cosmetic compositions of the invention are suitable for local application and can comprise additives and excipients commonly used in cosmetic preparations, such as preservatives, bactericidal agents, stabilizers, emulsifiers, buffers, dyes and other excipients.

[0080] The following examples are provided for illustrative purposes only of the present invention and are not to be understood as limiting the scope of protection, as can be seen from the enclosed claims.

Example 1

[0081] Formulation of cosmetic compositions according to the invention:

glyceryl stearate 1-5%

cetylstearyl (12) OE 1-5%

polysorbate 80 0.5-1%

cetyl alcohol 1-3%

octyldodecanol 1-3%

cetylstearylsonanoate 1-3%

triglyceride C8-I 10-20%

dimethylpolysiloxane 0.01-0.1%

wheat germ oil 0.8%

0.1% tocopheryl acetate

aloe vera 0.010%

7

CH 696 659 A9

matrichines: Glycyl-Histidyl-Lysine e

Glycyl-Glutaminyl-Prolyl-Arginine 0.001%

rutina 0.001%

Phaseolus lunatus extract 0.02%

sericin 0.1%

blood delexery extract 0.08%

chlorella algae extract 0.08%

peptide (Lis-Thr-Thr-Lis-Ser) 0.002%

saccharomices lysate 0.04%

enough antioxidants and preservatives enough water to 100

Example 2

[0082] Formulation of cosmetic emulsions according to the invention:

glyceryl stearate 2-5%

cetyl stearyl (12) OE 3-5%

polysorbate 80 0.5-1%

2-3% cetyl alcohol

octyldodecanol 3-4%

butyl alcohol (26) 0P (26) OE 0.8%

cetyl stearylenonate 2-3%

triglyceride C8_10 15-20%

dimethylpolysiloxane 0.08%

wheat germ oil 0.8%

tocopheryl acetate 0.2%

aloe vera 0.06%

matrichines: Glycyl-Histidyl-Lysine e

Glycyl-Glutaminyl-Prolyl-Arginine 0.001%

Rutina 0.01%

Phaseolus lunatus extract 0.02%

sericin 0.2%

blood vessels extract 0.25%

chlorella algae extract 0.3%

peptide (Lis-Thr-Thr-Lis-Ser) 0.001%

saccharomices lysate 0.35%

citric acid 0.2%

8

CH 696 659 A9

antioxidants / water perfume preservatives

Example 3 [0083]

glyceryl stearate cetyl stearyl (12) OE

polysorbate 80

cetyl alcohol octyododecanol butyl alcohol (26) 0P (26) OE

cetylstearylsonanoate triglyceride C8-i dimethylpolysiloxane wheat germ oil tocopheryl acetate aloe vera matrichine: Glycyl-Histidyl-Lysine and Glycyl-Glutaminyl-Prolyl-Arginine rutin phaseolus lunatus sericin extract blood extract seaweed extract chlorella peptide (Lis-Thr- Thr-Lis-Ser) saccharomices lysate citric acid antioxidants / water perfume preservatives just enough as needed to 100

4%

4%

0.5%

3.5%

2.8%

3%

2.5%

14%

0.08%

1.0%

12:35%

0.1%

0.002%

12:01%

0,03%

0.5%

0.5%

0.2%

0.001%

0.65%

0.2%

enough as needed to 100

Example 4 Effectiveness test

[0084] An in vivo study, under medical-dermatological control, was carried out on the cosmetic preparation of Example 3 for the evaluation of cosmetic efficacy in the treatment of stretch marks.

[0085] The study included 20 women between the ages of 18 and 45 with newly formed stretch marks (Striae rubrae). The volunteers used two different types of emulsion, one as a local treatment on stretch marks to be used with a special precision applicator and one as an integration product.

9

CH 696 659 A9

[0086] The methods of use of the products were the following: apply in the evening, for 30 consecutive days, about 2 ml of product for the local treatment directly over the striae to be treated, with a special precision applicator. Leave for 10 minutes, then massage over the strip until completely absorbed. The next morning, apply the integration product on stretch marks, massaging gently until completely absorbed.

[0087] The cosmetic efficacy was evaluated with a subjective evaluation by the volunteers participating in the trial, who after 4 weeks of treatment expressed their opinion regarding the following statements:

- the product reduces stretch marks

- the product makes stretch marks less noticeable

- the product reduces the color of stretch marks

- the product makes the skin more elastic

- the product makes the skin more hydrated

- the product makes the skin smoother

[0088] After the first 28 days of treatment, the following was highlighted:

- 45% of the volunteers reported that the products under examination reduce stretch marks;

- 60% of the volunteers reported that the products under examination make the stretch marks less evident;

- 60% of the volunteers reported that the products under examination attenuate the color of stretch marks;

- 60% of the volunteers reported that the products under examination make the skin more elastic;

- 100% of the volunteers reported that the products under examination make the skin more hydrated;

- 100% of the volunteers reported that the products under examination make the skin smoother.

Claims (1)

claims 1. Cosmetic composition for the treatment and / or prevention of skin stretch marks comprising the association of a base formulation comprising matrichine / e, rutin, phaseolus extract with one or more active principles selected from aloe vera extract, vitamin E, sericin, bloodline extract, Saccharomices lysate, chlorella algae extract, peptide including the Lis-Thr-Thr-Lis-Ser amino acid sequence and a cosmetically acceptable vehicle. 2. Cosmetic composition according to claim 1 wherein said matrichine is a peptide of Glycyl-Histidyl-Lysine or of Glycyl-Glutaminyl-Prolyl-Arginine or a mixture thereof. 3. Composition according to claim 1 or 2 wherein said Phaseolus is of the genus Phaseolus lunatus. 4. Cosmetic composition according to any of the claims from 1 to 3 comprising the matrichines of Glycyl-Histidyl-Lysine and Glycyl-Glutaminyl-Prolyl-Arginine, rutin, phaseolus lunatus extract, aloe vera extract, vitamin E, sericin, extract of Blood vessels, Saccharomices lysate, Chlorella algae extract, peptide with Lis-Thr-Thr-Lis-Ser amino acid sequence and a cosmetically acceptable vehicle. 5. Cosmetic composition according to any of the claims from 1 to 4 having the following formulation: glyceryl stearate 1-5% cetylstearyl (12) OE 1-5% polysorbate 80 0.5-1% cetyl alcohol 1-3% octyldodecanol 1-3% cetylstearylsonanoate 1-3% triglyceride Cs-ìo 10-20% dimethylpolysiloxane 0.01-0.1% wheat germ oil 0.8% 0.1% tocopheryl acetate aloe vera 0.010% matrichines: Glycyl-Histidyl-Lysine e 10 CH 696 659 A9 Glutaminyl-glycyl-prolyl-arginine 0.001% rutin 0.001% Phaseolus lunatus extract 12:02% sericine 0.1% blood delery extract 12:08% chlorella seaweed extract 12:08% peptide (Lis-Thr-Thr-Lis-Ser) 0.002% saccharomices lysate 12:04% enough antioxidants and preservatives enough water to 100 6. Cosmetic composition according to any of the claims from 1 to 4 having the following formulation: glyceryl stearate 2-5% cetyl stearyl (12) OE 3-5% polysorbate 80 0.5-1% 2-3% cetyl alcohol octyldodecanol 3-4% butyl alcohol (26) OP (26) OE 0.8% cetyl stearylenonate 2-3% Triglyceride Ce-10 15-20% dimethylpolysiloxane 0.08% wheat germ oil 0.8% tocopheryl acetate 0.2% aloe vera 0.06% matrichines: Glycyl Histidyl Lysine e Glycyl-Glutaminyl-Prolyl-Arginine 0.001% rutin phaseolus lunatus extract sericin delery extract blood extract chlorella peptide extract (Lis-Thr-Thr-Lis-Ser) saccharomices lysate citric acid antioxidants / water preservatives 0.01% 0.02% 0.2% 0.25% 0.3% 0.001% 12:35% 0.2% enough as needed to 100 11 CH 696 659 A9 perfume 7. Cosmetic composition according to any of the claims from 1 to 4 having the following formulation: glyceryl stearate 4% cetyl stearyl (12) OE 4% polysorbate 80 0.5% 3.5% cetyl alcohol octyldodecanol 2.8% butyl alcohol (26) OP (26) OE 3% cetylstearylsonanoate 2.5% triglyceride Cs-ìo 14% dimethylpolysiloxane 0.08% wheat germ oil 1.0% tocopheryl acetate 0.35% aloe vera 0.1% matrichines: Glycyl-Histidyl-Lysine e Glycyl-Glutaminyl-Prolyl-Arginine 0.002% Rutina 0.01% Phaseolus lunatus extract 0.03% sericin 0.5% 0.5% bloodline extract chlorella algae peptide extract (Lis-Thr-Thr-Lis-Ser) saccharomices lysate citric acid antioxidants / water perfume preservatives 0.2% 0.001% 0.65% 0.2% enough as needed to 100 8. A cosmetic composition according to any one of Claims 1 to 7, in a form suitable for local application. 9. Cosmetic composition according to claim 8 in a form selected from emulsion, gel, cream, milk, oil, solution. 10. A cosmetic method for treating and / or preventing the formation of stretch marks on the skin comprising the local application of a cosmetically effective quantity of a composition according to any of the claims from 1 to 9. 12